10534 seikagaku corporation the therapeutic polynucleotide and vector according to the present invention may advantageously be administered in the form of a gel that facilitates their transfection into the cells such a gel composition may be a complex of poly l lysine and lactose as described by midoux 1993 nucleic acids research 21 871 878 or also poloxamer 407 as described by pastore 1994 circulation 90 i 517 the therapeutic polynucleotide and vector according to the invention may also be suspended in a buffer solution or be associated with liposomes thus the therapeutic polynucleotide and vector according to the invention are used to make pharmaceutical compositions for delivering the dna genomic dna or cdna coding for the kal protein or one of its biologically active derivatives at the site of the injection the amount of the vector to be injected vary according to the site of injection and also to the kind of disorder to be treated as an indicative dose it will be injected between 0 1 and 100 u03bcg of the vector in a patient in another embodiment of the therapeutic polynucleotide according to the invention this polynucleotide may be introduced in vitro in a host cell preferably in a host cell previously harvested from the patient to be treated and more preferably.